Exciting Progress in the Fight Against Psoriasis
Last March, researchers at Rockefeller University published the results of a study that contained promising news for psoriasis sufferers.
Psoriasis is known for excessive skin-cell growth resulting in itchy, scaly patches. This process occurs when the human body’s immune system mistakenly attacks the skin – a reaction believed to be started by an immune-signaling molecule known as interleukin-23. Working off this theory in an experiment involving 31 patients, researchers applied human antibodies to target interleukin-23, hoping to prevent it from binding with skin-cell receptors.
The results were remarkable, with an average symptom improvement rate of 80%, and some patients seeing their symptoms disappear completely.
According to James Krueger, the study’s author and director of the Milstein Medical Research Program, this study, “raises the possibility of working toward long-term remission — in other words, a cure.”
Research is ongoing and we look forward to further developments. Meantime, it’s great to know that progress is being made in the fight to control, and eventually cure, psoriasis.
Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial